abstract: Renal allograft rejection is characterized by an influx of inflammatory cells. Interaction between infiltrating T cells and resident parenchymal cells might play an important role in the ongoing inflammatory response. The present study demonstrates that @entity11603 , a product of activated T cells, is locally expressed in kidneys undergoing rejection. Furthermore, during rejection, @entity2936 expression not only is present on most graft infiltrating cells but also is increased on resident @entity5115 ( @entity5115 ). To obtain more detailed insight in the consequences of T cell/ @entity5115 interaction, we analyzed the production of chemokines, including @entity687 ( @entity687 ), @entity2842 ( @entity2842 ) and regulated upon activation, normal T cell expressed and secreted ( @entity5737 ), and the production of @entity650 by cultured @entity1 primary @entity5115 in response to activation with @entity11603 in vitro. In addition, we studied the interaction with @entity4155 , a T-cell-specific cytokine previously demonstrated to be present during renal allograft rejection. The results, obtained by enzyme-linked immunosorbent assay, indicate that simultaneous activation of @entity5115 with @entity4155 and @entity11603 synergistically enhances production of @entity650 (2.1-fold higher than sum of single stimulations) and the chemokines @entity687 (15-fold) and @entity5737 (5.8-fold) as demonstrated by statistical analysis (P: < 0.05), whereas effects on @entity2842 (1.4-fold) are additive. Part of the synergy can be explained by increased @entity2936 expression on @entity5115 upon @entity4155 stimulation. The synergy is not unique for @entity5115 , because similar responses were found with @entity1 synoviocytes and a foreskin fibroblast cell line (FS4). Stimulation of @entity5115 with @entity11603 results in activation of NF-kappaB and induction of cytokine production by @entity4155 and @entity11603 is prevented by addition of the NF-kappaB inhibitor @entity13373 . These data suggest an important role for T cells in renal allograft rejection by acting on parenchymal cells via both soluble mediators and direct cellular contact.

title: Interleukin-17 and XXXX synergistically enhance cytokine and chemokine production by renal epithelial cells.

entities_list: @entity5115 :: ('MESH:C567703', 'Disease') :: ['TEC', 'tubular epithelial cells']

entities_list: @entity13373 :: ('MESH:C020972', 'Chemical') :: ['pyrrolidine dithiocarbamate']

entities_list: @entity2842 :: ('6347', 'Gene') :: ['MCP-1', 'monocyte chemoattractant protein-1']

answer: @entity11603 :: (959,Gene) :: ['CD40-ligand']


abstract: The most common @entity1 viruses have different abilities to establish persistent @entity281 . Virus-specific T-cell responses are critical in the control of virus replication and in the prevention of disease in @entity281 . A large number of phenotypic markers and a series of functions have been used to characterize virus-specific @entity404 + and @entity405 + T-cell responses, and these studies have shown great phenotypic and functional heterogeneity of the T-cell responses against different viruses. The heterogeneity of the T-cell response has been proposed to be specific to each virus. However, over the past 2 years, several studies have provided evidence that the phenotypic and functional heterogeneity of @entity404 + and @entity405 + T-cell responses is predominantly regulated by the levels of antigen load. The levels of antigen load modulate the phenotypic and functional patterns of the T-cell response within the same @entity778 . Furthermore, the functional characterization of virus-specific @entity404 + and @entity405 + T-cell responses has identified signatures of protective antiviral immunity. Polyfunctional, i.e. @entity1199 and @entity379 ( @entity379 ) secretion and proliferation, and not monofunctional, i.e. @entity379 secretion, @entity404 + and @entity405 + T-cell responses represent correlates of protective antiviral immunity in chronic @entity778 .

title: Functional signatures of protective antiviral T-cell immunity in XXXX @entity778 .

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['virus infections', 'virus infection']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['chronic infection']

entities_list: @entity379 :: ('3458', 'Gene') :: ['IFN-gamma', 'interferon-gamma']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity7660 are used as veterinary drugs for the treatment of food-producing animals. For consumer protection, legislation is in place to set limits for their residues. An enzyme-linked immunosorbent assay (ELISA) was developed which allowed, in a single reaction, the class-specific measurement of 11 @entity7660 , with limits of detection below European maximum residue limits. Determinations were feasible in milk, tissue, urine, and serum with simple and rapid sample preparation. In this format, the specific capture antibodies were precoated on the microtiter plate and horseradish peroxidase-labeled conjugate was used to compete with free @entity7660 . The stability of the precoated microtiter plate and conjugate was at least 1 year when stored at 2 to 8 degrees C; upon reconstitution, the conjugate was stable for 6 days at 2 to 8 degrees C. The stability of lyophilized @entity869 standards was at least 6 months when stored at 2 to 8 degrees C and at least 1 year when stored at -20 degrees C. A low cross-reactivity, 3.6%, was observed with @entity869 with open @entity3405 ring relative to 100% for intact @entity869 . Generic recognition was shown by relative cross-reactivity values ranging from 22 ( @entity11121 ) to 144% ( @entity16859 ). Cross-reactivity for @entity2886 was <0.1%. Intra- and interassay precisions expressed as coefficient of variation were typically 2-8%. The inhibitory concentration with 50% binding for @entity869 was typically 2 ppb. Recovery for different spiked levels was >70% with all the matrixes.

title: Stable competitive enzyme-linked immunosorbent assay kit for rapid measurement of 11 active XXXX in milk, tissue, urine, and serum.

entities_list: @entity3405 :: ('CHEBI:35627', 'Chemical') :: ['beta-lactam']

entities_list: @entity7660 :: ('MESH:D047090', 'Chemical') :: ['beta-lactams', 'Beta-lactams']

entities_list: @entity2886 :: ('MESH:D002511', 'Chemical') :: ['cephalosporins']

entities_list: @entity11121 :: ('MESH:D010404', 'Chemical') :: ['penicillin V']

entities_list: @entity869 :: ('MESH:D000667', 'Chemical') :: ['ampicillin']

entities_list: @entity16859 :: ('MESH:D009254', 'Chemical') :: ['nafcillin']

answer: @entity7660 :: (MESH:D047090,Chemical) :: ['beta-lactams']


abstract: In this study, the effect of the synthetic glucocorticoid hormone @entity619 ( @entity3784 ) on HSV replication was studied in a @entity3784 receptor-positive @entity19 @entity521 ( @entity521 ) cell line. In cells treated with 10(-7) M @entity3784 and then infected with HSV, there was a statistically significant 9-18-fold increase in the amount of virus produced in these cells compared to untreated controls. Adsorption kinetic studies with HSV were performed in @entity3784 -treated @entity521 cells and untreated controls. It was found that there was a significant increase in the adsorption rate of HSV in the @entity3784 -treated cells as compared with the controls. During the course of these studies, a strain of @entity521 cells was noted to have lost its ability to stimulate HSV replication following @entity3784 treatment. Receptor binding assays were performed on cytosols prepared from @entity521 cells that responded with an increase in HSV titers to @entity3784 treatment and the new strain of @entity521 cells that was @entity3784 refractile. These latter cells were found to have lost their @entity3784 receptors. These results indicate that the modulation of HSV replication of @entity3784 treated cells was regulated by the presence of @entity3784 receptors in these cells. Once lost, the cells do not respond to @entity3784 treatment with increased HSV replication. These observations may lead to a clinical assay to determine @entity1 with high glucocorticoid levels who may be at risk of recurrent @entity281 .

title: Hormonal modulation of herpes simplex virus replication in a XXXX @entity521 cell line.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['herpes infections']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['NB', 'neuroblastoma']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: PURPOSE: Anterior spinal stapling for the treatment of adolescent idiopathic @entity1635 has been shown to slow progression in small curves; however, its role in larger curves remains unclear. The purpose of this study was to evaluate the effectiveness of @entity5648 staples to modulate spinal growth by evaluating the two-dimensional and three-dimensional morphological and histological effects of this method in a well-established porcine model. METHODS: Three immature Yucatan miniature @entity1707 underwent intervertebral stapling. Two staples spanned each of three consecutive mid-thoracic discs and epiphyses. Monthly radiographs were obtained. Computed tomography (CT) was conducted at harvest after 6  months of growth. Measurements of wedging and height for each disc and vertebral body were conducted. Micro CT was used to compare physeal closure between stapled and non-stapled levels. Histology of the growth plate also compared the @entity1184 zone thickness for control and stapled vertebrae. RESULTS: After 6  months of stapled growth, the average coronal Cobb angle of the stapled segments increased by 7.7      2.0   and @entity1513 increased by 3.3      0.6   compared to preoperative curves. Increased @entity13949 and decreased disc height (p  <  0.001) were noted in stapled regions. Overall, 26      23  % of each growth plate was closed in the stapled segments, with 6      8  % closure in the unstapled levels. No difference was observed regarding the @entity1184 zone height when comparing instrumented to uninstrumented levels, nor was a difference recognized when comparing right versus left regions within stapled levels alone. CONCLUSIONS: Six months of @entity5648 intervertebral stapling created a mild coronal and @entity85 associated with reduced vertebral and disc height, and increased coronal vertebral and sagittal disc wedging.

title: The modulation of spinal growth with XXXX intervertebral stapling in an established @entity1707 model.

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['scoliosis']

entities_list: @entity13949 :: ('MESH:C537350', 'Disease') :: ['vertebral wedging']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['sagittal deformity']

answer: @entity5648 :: (MESH:C013616,Chemical) :: ['nitinol']


abstract: OBJECTIVE: To evaluate the usefulness of ultrasonography (USG) in the detection of adult filariae in rodents. @entity10065 are frequently detected using USG in @entity1 , whereas adult @entity2757 have not been so far. METHODS: A Meriones unguiculatus with @entity281 was examined to visualize adult filariae of a similar length as @entity10065 . Similarly, three Mastomys coucha, infected with @entity2757 , were examined using USG to verify whether the adult worms, which are far smaller than @entity10065 and L. sigmodontis, can be located using USG in the animals. RESULTS: Adult L. sigmodontis were detected using USG in the @entity1143 of M. unguiculatus, and in M. coucha adult @entity2757 were visualized in the hearts, lungs, axillary lymph nodes and scrotum. Ultrasound findings were verified by dissection of the rodents. CONCLUSIONS: Although adult @entity2757 are far smaller than L. sigmodontis and @entity10065 , they can be detected using USG in rodents. USG may serve as an adjunctive tool to support parasitological examinations and can add information on filarial infections at any time point of an observation period, particularly in cryptic infections and without the need for invasive measures or killing of the rodent. Thus, USG can support the early detection of macrofilaricidal activities of new compounds and can be used to determine the location of adult worms in the animals. It is possible to give a rough estimate of the number of adult worms, but determination of the exact numbers of adult filariae in various locations is impossible with USG.

title: Ultrasonography in filaria-infected rodents: detection of adult Litomosoides sigmodontis and XXXX filariae.

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural cavity']

entities_list: @entity2757 :: ('6279', 'Species') :: ['Brugia malayi', 'B. malayi']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['Litomosoides sigmodontis infection']

entities_list: @entity10065 :: ('6293', 'Species') :: ['W. bancrofti', 'Wuchereria bancrofti']

answer: @entity2757 :: (6279,Species) :: ['Brugia malayi']


abstract: Hyperplasia of synovial membrane in @entity309 ( @entity309 ) is a critical pathological foundation for inducing @entity130 . The janus kinase and signal transducer and activator of transcription (Jak-STAT) pathway plays a critical role in synovial membrane proliferation induced by platelet-derived growth factor (PDGF). To explore the anti-cell proliferation mechanism of @entity49042 , a pure monomer extracted from Chinese medical plant zedoary rhizome, the changes of @entity4016 - @entity24779 signal pathway-related molecules in synoviocytes were observed in vitro. In this study, the fibroblast-like synoviocytes (FLS) in @entity1 with @entity309 were collected and cultured. The following parameters were measured: cell proliferation (WST-1 assay), cell cycles (fluorescence-activated cell sorting, FACS), @entity6897 and @entity4104 activities (electrophoretic mobility shift assay, EMSA), and the protein expressions of phosphorylated @entity4016 , @entity6897 , and @entity4104 (Western blot). It was shown that @entity49042 could inhibit the @entity309 -FLS proliferation and DNA synthesis induced by PDGF-BB in a dose-dependent manner in vitro. The transcription factors activities of @entity6897 and @entity4104 were obviously elevated after PDGF-BB stimulation (P < 0.05). Super-shift experiments identified the @entity6897 or @entity4104 proteins in the complex. Furthermore, the different concentration @entity49042 could downregulate the DNA binding activities of @entity6897 and @entity4104 (P < 0.05) and inhibit the phosphorylation of @entity4016 while it had no effect on the protein expressions of @entity6897 and @entity4104 . Positive correlations were found between changes of cell proliferation and DNA-binding activities of @entity6897 and @entity4104 , respectively (P < 0.01). In conclusion, @entity49042 might suppress the FLS proliferation and DNA synthesis induced by PDGF-BB through attenuating @entity4016 phosphorylation, downregulating @entity6897 and @entity4104 DNA-binding activities, which could provide theoretical foundation for clinical treatment of @entity309 .

title: Inhibitory Effect of @entity49042 on @entity4016 -STAT Signal Pathway Molecules of Fibroblast-Like Synoviocytes in @entity1 with XXXX .

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['articular injury']

answer: @entity309 :: (MESH:D001172,Disease) :: ['Rheumatoid Arthritis']


abstract: This case study compares two different clinical outcomes for a @entity1 with a long-standing @entity914 prescribed @entity1088 on two occasions. During the first trial, @entity1088 was used at a higher dose for this @entity1 (350-450mg/day) and included clinically significant @entity4164 , @entity55 , and @entity55 -like illnesses requiring immediate medical intervention including hospitalization. There were also @entity1 complaints of @entity1295 , cough, choking, and constipation leading to poor adherence. @entity1088 was discontinued when the @entity1 withdrew his consent due to side effects, despite his awareness of its benefits, including reduction of command @entity1833 and @entity146 . The second @entity1088 trial was associated with lower daily doses and therapeutic serum blood levels. The @entity1 was actively participating in and adhering to the medication plan. A very narrow window of @entity1088 dose was exceeded for two days and the @entity1 complained of @entity4164 , cough, and lethargy. He was subsequently hospitalized for a two week period to treat @entity1174 . This hospitalization helped establish the ideal daily dose of @entity1088 for this @entity1 and also brought the relationship between @entity1174 and @entity1088 to the attention of the psychiatrist and medical specialist. Once the appropriate dosage for this @entity1 was established, his @entity716 and affective symptoms were controlled, he was not hampered by adverse side effects, and he started to actively participate in social and recreational activities and plans that culminated in discharge from a state psychiatric facility to a supportive community residence. It is our hope that the lessons we have learned from our shared experience with this @entity1 will be of benefit to other clinicians and @entity1 .

title: XXXX and @entity1174 : a case study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1088 :: ('MESH:D003024', 'Chemical') :: ['Clozapine', 'clozapine']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritability']

entities_list: @entity4164 :: ('MESH:D012798', 'Disease') :: ['sialorrhea', 'hypersalivation']

entities_list: @entity914 :: ('MESH:D011618', 'Disease') :: ['psychotic disorder']

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucinations']

entities_list: @entity1174 :: ('MESH:D011015', 'Disease') :: ['aspiration pneumonia']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic']

answer: @entity4164 :: (MESH:D012798,Disease) :: ['Sialorrhea']


abstract: The heterodimeric subunits of @entity38254 kinase (dAK)- @entity16614 kinase ( @entity51044 ) from @entity9206 R-26 exhibit contrasting conformations manifested in the nearly unidirectional heterotropic activation of dAK when @entity51044 binds @entity16614 . This is mediated, in part, by the conserved Ras switch I-like sequence (residues 153-161) [Guo et al. (1997) J. Biol. Chem. 272, 6890-6897]. In an attempt to identify domains differentiating the specificities of dAK and @entity51044 , we constructed several chimeras splicing heterodimeric dAK within this region. In Chimera-III, dAK residues 120-170 were replaced by the homologous section of @entity51044 . dAK activity was elevated 40%, but although it retained its original specificity and Km values, it could no longer be activated by @entity16614 . Moreover, both the activated dAK and the "dAK" of Chimera-III exhibited (i) an increased Ks for the leading substrate @entity855 -Mg2+, suggesting the formation of intermediate enzyme species along their respective kinetic pathways, and (ii) broadened and lower pH optima for the dAK activities. These observations further indicate the importance of dAK residues 120-170, including the Ras-like segment, in catalysis and heterotropic activation. The other conformational properties of dAK (e.g. self-inactivity and MgATP being the leading substrate) were unaltered by this substitution, thus localizing the responsible domains even further upstream.

title: Functional assignment by Chimera construction of the domain affecting heterotropic activation of @entity38254 kinase from XXXX R-26.

entities_list: @entity9206 :: ('1579', 'Species') :: ['Lactobacillus acidophilus']

entities_list: @entity16614 :: ('MESH:D003849', 'Chemical') :: ['deoxyguanosine']

entities_list: @entity38254 :: ('MESH:D003839', 'Chemical') :: ['deoxyadenosine']

answer: @entity9206 :: (1579,Species) :: ['Lactobacillus acidophilus']


abstract: The class C subset of vacuolar protein sorting (Vps) proteins ( @entity37670 , @entity45276 , @entity45277 and Vps33) assembles into a vacuole/prevacuole-associated complex. Here we demonstrate that the class C-Vps complex contains two additional proteins, @entity45278 and @entity37955 . The @entity1473 -terminal 148 @entity1522 of @entity45278 direct its association with the class C-Vps complex by binding to @entity37670 . A previous study has shown that a large protein complex containing @entity45278 and @entity37955 functions as a downstream effector of the active, @entity3007 -bound form of Ypt7, a rab GTPase required for the fusion of vesicular intermediates with the vacuole (Price, A., D. Seals, W. Wickner, and C. Ungermann. 2000. J. Cell Biol. 148:1231-1238). Here we present data that indicate that this complex also functions to stimulate @entity377 exchange on Ypt7. We show that @entity45278 directly binds the @entity3006 -bound and @entity377 -free forms of Ypt7 and that purified @entity45278 stimulates @entity377 exchange on Ypt7. We propose that the class C-Vps complex both promotes @entity45278 -dependent @entity377 exchange on Ypt7 and, based on the work of Price et al., acts as a Ypt7 effector that tethers transport vesicles to the vacuole. Thus, the class C-Vps complex directs multiple reactions during the docking and fusion of vesicles with the vacuole, each of which contributes to the overall specificity and efficiency of this transport process.

title: New component of the vacuolar class C-Vps complex couples XXXX exchange on the Ypt7 GTPase to SNARE-dependent docking and fusion.

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

answer: @entity377 :: (CHEBI:36976,Chemical) :: ['nucleotide']


abstract: BACKGROUND: The risk of endobronchial ultrasound-guided transbronchial biopsy-related pneumothorax is a major concern and warrants further studies. The aim of our study was to estimate the risk of pneumothorax after this procedure and identify its risk factors. METHODS: From 2007 to 2011, 399 @entity1 who underwent endobronchial ultrasound-guided transbronchial biopsy for @entity358 were included in this study. The variables analyzed included @entity1 factors, lesion factors and procedure factors. Multivariate logistic regression analysis was used to identify independent risk factors for pneumothorax. RESULTS: The incidence of pneumothorax was 3.3% (13/399). Chest tube placement was required for 31% (4/13) of pneumothoraces. Independent risk factors for pneumothorax included @entity2542 (OR, 55.09; 95% CI, 9.37-324.03; p<0.001) and probe position adjacent to the lesion (OR, 17.01; 95% CI, 2.85-101.64; p=0.002). The number of biopsy specimens, age, sex, history of prior lung surgery and lesion size, location and character did not influence the risk of pneumothorax in our analyses. CONCLUSIONS: The risk of pneumothorax after endobronchial ultrasound-guided transbronchial biopsy is low. To further reduce the risk of pneumothorax, every effort should be made to advance the endobronchial ultrasound probe into the bronchus where it is imaged within the @entity75 before embarking on transbronchial biopsy.

title: Risk factors of pneumothorax after endobronchial ultrasound-guided transbronchial biopsy for XXXX .

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['peripheral lung lesions']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion']

entities_list: @entity2542 :: ('MESH:D011656', 'Disease') :: ['pulmonary emphysema']

answer: @entity358 :: (MESH:D008171,Disease) :: ['peripheral lung lesions']


abstract: OBJECTIVE: The correction of sinus venosus @entity118 with a @entity358 to the superior vena cava has been associated with @entity1817 . We present our follow-up of 2 approaches of managing the lesion and compare their postoperative results. METHODS: Forty @entity1 underwent operation between March 1999 and January 2005, of whom 37 @entity1 (aged 3-50 years) are on follow-up. These @entity1 were divided into 2 groups: single-patch repair (group A, 18 @entity1 ) and double-patch repair (group B, 19 @entity1 ). Echocardiography and electrocardiography were performed 7 days after surgery and during the subsequent follow-up. RESULTS: The mean duration of follow-up was 22.56 months. There were no postoperative @entity204 or residual defects. Six @entity1 in group A and 2 @entity1 in group B had turbulence and a significant superior vena cava-right atrium pressure gradient of more than 6 mm Hg. Nine @entity1 in group A had a significant gradient causing turbulence across the right superior pulmonary vein at the level of the patch, whereas no @entity1 in group B had turbulence across the pulmonary vein. Four @entity1 in group A and no @entity1 in group B had postoperative rhythm abnormalities on late follow-up. There was no other complication. CONCLUSIONS: Partial @entity358 can be safely managed with multiple techniques with low morbidity. The double-patch technique is technically reproducible and offers better results in terms of superior vena cava narrowing and gradient across the pulmonary vein without any increase in complications.

title: Comparative study of single- and double-patch techniques for sinus venosus @entity118 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1817 :: ('MESH:D012804', 'Disease') :: ['obstruction to the venous return and sinus node dysfunction']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['partial anomalous pulmonary venous connection', 'anomalous pulmonary venous connection']

entities_list: @entity118 :: ('MESH:D006344', 'Disease') :: ['atrial septal defect']

answer: @entity358 :: (MESH:D008171,Disease) :: ['partial anomalous pulmonary venous connection']


abstract: BACKGROUND: The @entity209 is associated with an increased risk of @entity6 and @entity65 . However, only the @entity6308 waist (HTGW) criterions have been chosen for their ability to identify a group of @entity1 with a higher cardiovascular risk independently of the traditional risk factors. AIM: The aim of this study was to examinate the real concordance of the @entity209 according to the HTGW definition, National @entity165 Education Program Adult Treatment Panel III (NCEP ATP III) definition and the International @entity6 Federation (IDF) definition. We also evaluated the prevalence of the @entity209 in a French population. METHOD: The study was conducted on a sample of 232 @entity1 , of both sexes, aged from 30 to 65 years old, recruited in general practice. @entity1 had a medical examination, and biological analyses were performed to assess their metabolic status. RESULTS: Kappa concordance coefficient was 0.46 between HTGW and NCEP ATP III; it was 0.43 between HTGW and IDF, and 0.59 between NCEP ATP III and IDF. The prevalence of the @entity209 according to the HTGW in the sample was 16.8%, 18.3% in @entity1 and 15.4% in @entity1 . According to NCEP ATP IlI prevalence were respectively 20.3%, 20.9%, and 19.7%. According to IDF they were respectively 28.4%, 33%, and 23.9%. CONCLUSION: We recommend paying the same attention to the @entity209 than to the traditional cardiovascular risk factors, and we recommend the use of the HTGW definition as diagnostic tool.

title: [Concordance between three definitions for XXXX ( @entity6308 waist, National @entity165 Education Program, International @entity6 Federation), and prevalence of the syndrome in a French population].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity6308 :: ('MESH:D064250', 'Disease') :: ['Hypertriglyceridemic']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol']

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: @entity309 ( @entity309 ) is a disease full of variety. We need to elucidate various clinical doubts for the complete cure of @entity309 . We observed a lot of @entity1 with @entity8344 ( @entity8344 ) @entity281 who developed to @entity309 till now. We investigated @entity8344 @entity281 in relation with @entity309 etiology. @entity8344 infects persistently to immune cells through cell surface Ku80 autoantigen as a cellular receptor. We are able to detect @entity8344 in immune cells which infiltrate in synovial tissues of @entity1 with @entity309 . @entity8344 is activated in infected cells, and functional viral protein @entity8768 induces over production of inflammatory cytokine TNFalpha. As a result, it promotes a neutrophile activation and migration to the synovium where there are @entity8344 -infected immune cells. This may cause @entity625 and create a vicious circle of chronic @entity32 that develops into @entity309 . As for the @entity8344 persistent @entity281 to immune cells, abnormality of anti- @entity8344 humoral immunity may participate in imperfection of @entity8344 neutralization of a host. It is expected the development of effective treatment that cure progressing @entity309 from @entity8344 @entity281 . @entity8768 may be one of the candidates of therapeutic target.

title: [Approach from bedside to etiology/pathophysiology/treatment of XXXX ].

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: OBJECTIVE: Islet allotransplantation is a less invasive alternative to surgical @entity2316 , while @entity4294 ( @entity4294 ) is usually performed after pancreatic surgery to prevent @entity6 . Our aim was to assess the feasibility, radiological aspects, complications and clinical outcome of @entity4294 following pancreatic surgery for not only chronic @entity788 but also benign and malignant nodules. METHODS: From 2008 to 2012, 41 @entity1 were enrolled for @entity4294 12-48   h after pancreatic surgery (extended pancreatic surgery for chronic @entity788 and @entity5 ). @entity4294 was performed using a combined ultrasonography and fluoroscopy-guided technique (4-F catheter). @entity4294 feasibility, median follow-up and metabolic (insulin independence rate, graft function based on C-peptide levels) and oncologic outcomes were recorded. RESULTS: @entity4294 was not performed in 7/41 @entity1 (4 cases for an inadequate islet mass, 2 cases for @entity1344 and 1 case for islet culture contamination), while it was successfully performed in 34/34 @entity1 . Procedure-related major complications occurred in four @entity1 : two bleedings requiring transfusions, one @entity1 with left portal vein @entity715 and one @entity1 with @entity295 . Median follow-up duration was 546 days. Insulin independence was achieved in 15/34 (44%) @entity1 , partial graft function in 16/34 (47%) @entity1 and no function in 3/34 (9%) @entity1 . None of the 17 @entity1 with malignant nodules developed liver metastases during follow-up. CONCLUSION: @entity4294 , performed under ultrasound and fluoroscopy combined guidance and not requiring immunosuppression, is feasible, with a relatively low complication rate and a better metabolic outcome than allotransplantation. ADVANCES IN KNOWLEDGE: @entity4294 can prevent pancreatogenic @entity6 . Ultrasound is a useful tool for the guidance and monitoring of @entity4294 .

title: Single-centre experience of extending indications for @entity4294 ( XXXX ) after pancreatic surgery to prevent @entity6 : feasibility, radiological aspects, complications and clinical outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity4294 :: ('MESH:D007516', 'Disease') :: ['percutaneous intraportal islet autotransplantation', 'PIPIAT']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['pancreas transplantation for Type 1 diabetes']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['benign/malignant neoplasms']

entities_list: @entity1344 :: ('MESH:D043171', 'Disease') :: ['haemodynamic instability']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

answer: @entity4294 :: (MESH:D007516,Disease) :: ['PIPIAT']


abstract: BACKGROUND: Despite important advances in the therapy of @entity3052 ( @entity3052 ), the majority of @entity1 die of their disease, unless bone marrow transplantation (BMT) is done. Infection and @entity548 are still the major causes of mortality in @entity3052 @entity1 . Progress in therapy and supportive care has led to gradual improvement in the overall results, but further improvements are still needed. @entity1 AND METHODS: The aim of this study is to identify the outcome and costs of @entity3052 @entity1 treated with conventional chemotherapy (CCT) at the National @entity5 Institute (NCI), Cairo University during the time period from April 1999 to January 2002. Clinical, laboratory characteristics were all recorded. Data regarding different types of therapies given for these @entity1 including response, outcome and costs were also collected. RESULTS: The median age of 82 identified @entity3052 @entity1 was 34 years. The complete remission (CR) rate after induction with CCT was 52% (42/82 @entity1 ) with a median CR duration of 9 months. Twenty-eight percent of @entity1 who achieved CR subsequently relapsed. By January 2003, fifty-eight @entity1 were dead (70.7%). Infections were the major mortality cause, followed by @entity548 (65% , 28% and 7% respectively). The median treatment cost per @entity1 was 33158 Egyptian Pounds (LE). It was higher for @entity1 who achieved CR compared to those who relapsed and/or died. Drugs contributed by 78 % to the total treatment cost, while hospitalization, investigations and blood-component therapy contributed by 6%, 7% and 8% respectively. CONCLUSIONS: Outcome of @entity1 with @entity3052 treated at NCI- Cairo University can be enhanced by improvement of supportive therapy; mainly infection control and expanding BMT programs to accommodate all eligible @entity1 .

title: Cost and outcome of treatment of adults with XXXX at the National @entity5 Institute-Egypt.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['disease progression then bleeding', 'hemorrhage']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'adult AML', 'AML']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']


abstract: OBJECTIVE: To explore @entity308 from a gender perspective, by capturing depressed @entity1 's and @entity1 's formulations of their experiences and understanding of their situation. DESIGN: Qualitative interview study. SETTING: A healthcare centre in northern Sweden. SUBJECTS: Eighteen @entity1 who had been diagnosed with @entity308 and treated for at least 6 months were interviewed in depth, both @entity1 and @entity1 of different ages and social status. Open questions were posed around the themes of Malterud's key questions, focusing especially on how the informants conveyed their experiences. Interviewing and qualitative data analysis went on simultaneously. RESULTS: The experience of @entity308 held similarities for @entity1 and @entity1 , but the outward manifestations differed by gender as well as socioeconomic status. Though experiences of high demands underlay the narratives of all informants, home or work had different priority. @entity1 talked more easily about physical distress--often the heart--than about emotions. @entity1 verbalized more readily emotional distress--shame and guilt--while physical symptoms often revolved around the stomach. @entity1 dealt with insecurity by aggrandizing their previous competence, @entity1 by self-effacement. CONCLUSION. As clinicians we must listen attentively not only to the manifest but to the avoided or unarticulated. By doing so we might counteract normative gender patterns that highlight the @entity308 of @entity1 and conceal that of @entity1 .

title: Beyond weeping and crying: a gender analysis of expressions of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'Men', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: INTRODUCTION: Rapidly conducted @entity4710 ( @entity4710 ) can lead to inappropriate device therapy in @entity737 ( @entity737 ) @entity1 . We sought to determine the incidence of @entity4710 and the occurrence of inappropriate @entity737 therapy due to SVT in a pediatric and young adult population. METHODS AND RESULTS: We undertook a retrospective review of clinical course, Holter monitoring, and @entity737 interrogations of @entity1 receiving @entity737 follow-up at our institution between March 1992 and December 1999. Of 81 new @entity737 implantations, 54 eligible @entity1 (median age 16.5 years, range 1 to 48) were identified. Implantation indications included @entity1163 and/or spontaneous/inducible @entity943 with @entity299 (30), @entity1162 (9), structurally normal heart ( @entity1165 / @entity2224 [VT/VF]) (7), and @entity296 (7). Sixteen @entity1 (30%) received a dual-chamber @entity737 . SVT was recognized in 16 @entity1 , with 12 of 16 having inducible or spontaneous @entity591 . Eighteen @entity1 (33%) received > or =1 appropriate shock(s) for VT/VF; 8 @entity1 (15%) received inappropriate therapy for SVT. Therapies were altered after an inappropriate shock by increasing the detection time or rate and/or increasing beta-blocker dosage. No single-chamber @entity737 was initially programmed with detection enhancements, such as sudden onset, rate stability, or QRS discriminators. Only one dual-chamber defibrillator was programmed with an atrial discrimination algorithm. Appropriate @entity737 therapy was not withheld due to detection parameters or SVT discrimination programming. CONCLUSION: SVT in @entity1 and young adults with ICDs is common. Inappropriate shocks due to SVT can be curtailed even without dual-chamber devices or specific SVT discrimination algorithms.

title: XXXX in @entity1 and young adults with implantable cardioverter defibrillators.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathies']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['long QT syndrome']

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['ICD', 'implantable cardioverter defibrillator']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['atrial tachycardias']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['congenital heart disease']

entities_list: @entity4710 :: ('MESH:D013617', 'Disease') :: ['supraventricular tachycardias', 'SVTs']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia']

answer: @entity943 :: (MESH:D001145,Disease) :: ['Supraventricular arrhythmias']


abstract: The role of Bacillus Colmette-Gu  rin (BCG) as an adjuvant in autologous @entity5 vaccines was examined. In nine @entity1 with @entity1358 , @entity5 cells alone (wild-type, WT) or with BCG were inoculated intradermally into contralateral thighs. Seven to 10 days later, the draining vaccine-primed lymph nodes (WT-VPLN and BCG-VPLN) were excised. BCG increased the number of harvested VPLN cells by 10-fold (mean +/- SE = 61.8 +/- 20.6/x10(-7)/ @entity1 ). BCG-VPLN had significantly greater percentages of CD3(+) and @entity404 (+) T cells compared to WT-VPLN. Both groups of VPLN cells were activated in vitro with anti-CD3 or anti-CD3/ @entity1361 mAbs followed by expansion in @entity1199 . Anti-CD3/ @entity1361 activation resulted in greater expansion of @entity404 (+) T cells compared to anti-CD3. After activation, VPLN cells were stimulated with irradiated autologous @entity5 targets and cytokines ( @entity379 , @entity2841 , @entity688 ) released into the supernatants were measured 24 h later. Anti-CD3/ @entity1361 -activated BCG-VPLN cells were found to have a greater release of @entity379 compared with that of WT-VPLN cells, which was not observed significantly with @entity688 or @entity2841 . BCG resulted in increased VPLN cell yield as well as enhanced type 1 ( @entity379 release) immune responses of VPLN cells to autologous @entity5 without upregulating type 2 ( @entity688 release) responses. Anti-CD3/ @entity1361 was superior to anti-CD3 activation in this cellular response.

title: Immunological effects of BCG as an adjuvant in autologous XXXX vaccines.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'irradiated tumor']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: Loading of the lunate in @entity1 with @entity195 and a negative ulnar variance provide the rationale for a radial shortening osteotomy. This osteotomy decreases forces transmitted from the radius to the lunate. We retrospectively reviewed 12 @entity1 with @entity195 who had 13 radial shortening osteotomies to ascertain whether the reported short- and medium-term results endured in the long-term. We evaluated nine osteotomies in nine of the 12 @entity1 with a minimum of 16 years followup (average, 22 years; range, 16-31 years). Three @entity1 died and one was lost to followup. For the nine @entity1 , the range of motion was impaired compared with the normal side. Grip strength was on average 90% of the unaffected side. The average visual analog scale score for @entity158 was 2.4 and the average Disabilities of the Arm, Shoulder, and Hand score was 14 at latest followup. In eight @entity1 , the Lichtman classification of @entity195 did not change at followup, but in three @entity1 there was radiographic progression of the disease, which occurred during the first 10 years postoperatively. The medium- and long-term results therefore were comparable. We recommend radial shortening in stable wrists (Stage 3A or less) with a negative ulnar variance. The radius should be shortened to the level of the ulna, normally 4 to 6 mm, after which stable (plate) fixation should be performed under compression.

title: Outcome of XXXX 22 years after distal radius shortening osteotomy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Kienb  ck's disease"]

answer: @entity195 :: (MESH:D000544,Disease) :: ['Kienb  ck's disease']


abstract: Two @entity1 successfully treated for @entity263 developed a progressive @entity16 beginning with loss of @entity1319 followed by severe, persistent @entity2473 of the face, jaw, and pharynx. Both had mild gait unsteadiness, and one exhibited @entity2045 . Extensive diagnostic studies, including MRIs of the brainstem (with and without contrast), were normal. CSF examination showed mild pleocytosis and elevated IgG. Quantitative eye movement recordings documented selective involvement of voluntary horizontal saccades with sparing of @entity1319 . Neither patient had antineuronal antibodies in the blood. Postmortem examination revealed perivascular chronic inflammatory cells and microglial infiltration of the pons and medulla. One @entity1 also had perivascular infiltrates in both mesial temporal lobes. Neuronal loss was localized to the pontine tegmentum, the medullary sensory nuclei, and the cerebellum. Brainstem motor nuclei were preserved. The clinical and pathologic findings suggest an @entity792 (probably paraneoplastic) with selective damage to a subpopulation of brainstem neurons critical for @entity1319 and recurrent inhibition of bulbar nuclei.

title: Novel brainstem syndrome associated with XXXX .

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic cancer']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['facial and abdominal myoclonus']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic syndrome']

entities_list: @entity2473 :: ('MESH:D013035', 'Disease') :: ['muscle spasms']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune process']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ['horizontal eye movements', 'voluntary horizontal eye movements', 'horizontal slow eye movements']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate carcinoma']


abstract: A 65-year-old @entity1 was admitted to our hospital because of thirstyness and left lower @entity490 . On admission, he was found to have @entity1791 , @entity177 (BUN: 73 mg/dl, Crt: 4.4 mg/dl), and @entity2741 (13.2 mg/dl). Chest X-ray films and computed tomograms showed enlargement and @entity730 of the hilar lymph nodes, and thickened interlobar fissures in both lungs. Levels of @entity1289 (30.2 IU/l) and 1.25 ( @entity2145 )2VitD3 (66.4 pg/ml) were elevated. Histologic examination of the specimen obtained from transbronchial lung biopsy showed non-caseous epithelioid cell @entity738 . Because the level of parathyroid hormone was normal and no @entity5 were detected, a diagnosis of @entity370 was made. Treatment with extracorporeal shock wave lithotripsy, transurethral lithotomy, saline infusion, and @entity617 (30 mg/day) alleviated the @entity1791 , @entity177 , and @entity2741 . After discharge, the @entity1 was followed up and given @entity617 therapy. About 1 month after the @entity617 dose had been tapered to 15 mg/day, the @entity1 experienced @entity1353 and facial and pedal @entity4 . Because @entity712 was diagnosed, he was re-admitted to our hospital for a second time. Although he was then placed on intensive therapy, he died of @entity1165 associated with @entity370 of the heart.

title: [ @entity370 with XXXX , @entity1791 , @entity177 , and @entity712 ].

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity370 :: ('MESH:D012507', 'Disease') :: ['sarcoidosis']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['calcification']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1791 :: ('MESH:D052878', 'Disease') :: ['urolithiasis']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity2741 :: (MESH:D006934,Disease) :: ['hypercalcemia']


abstract: Appropriate antibiotic treatment reduces the duration of symptoms associated to @entity55 , the risk of complications and mortality. In most cases, it is not possible to identify the etiologic agent so antibiotic treatment is empirically prescribed. In Chile, one third of @entity328 isolates has diminished susceptibility to @entity114 ; in-vitro @entity2929 resistance is about 10-15% and @entity3524 resistance 2-10%. It is recommended to classify @entity1 with @entity497 acquired @entity55 in four risk categories: Group 1: @entity1 under 65 years without co-morbidities, in ambulatory attendance. TREATMENT: oral @entity115 1 g TID, 7 days. Group 2: @entity1 over 65 years and / or co-morbidities, in ambulatory attendance. TREATMENT: oral @entity115 / @entity798 500/125 mg TID or 875/125 mg BID, or @entity2261 500 mg BID, 7 days. Group 3: @entity1 admitted to general wards with criteria of moderate severity. TREATMENT: @entity2756 1-2 g once a day or @entity3524 1 g TID, IV, 7-10 days. Group 4: @entity1 with severe @entity9527 that must be interned into ICU. TREATMENT: @entity2756 2 g once a day or @entity3524 1 g TID, IV, associated to @entity2929 500 QID, @entity800 500-1.000 mg once a day, or @entity3477 400 mg/once a day, IV, 10-14 days. In the presence of @entity566 to or treatment failure with betalactam drugs and/or positive serology for @entity9463 , @entity1047 or Legionella sp it is recommended to add: @entity2929 500 mg QID, IV or oral, oral @entity4581 500 mg BID, or oral @entity4580 500 mg once a day.

title: [Treatment of @entity497 -acquired XXXX in adults].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2261 :: ('MESH:D002444', 'Chemical') :: ['cefuroxime']

entities_list: @entity2756 :: ('MESH:D002443', 'Chemical') :: ['ceftriaxone']

entities_list: @entity9463 :: ('MESH:D009175', 'Disease') :: ['Mycoplasma']

entities_list: @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin']

entities_list: @entity3477 :: ('MESH:C104727', 'Chemical') :: ['moxifloxacin']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity114 :: ('MESH:D010406', 'Chemical') :: ['penicillin']

entities_list: @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin']

entities_list: @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin']

entities_list: @entity1047 :: ('MESH:D002690', 'Disease') :: ['Chlamydia']

entities_list: @entity798 :: ('MESH:D019818', 'Chemical') :: ['clavulanate']

entities_list: @entity4580 :: ('MESH:D017963', 'Chemical') :: ['azythromycin']

entities_list: @entity3524 :: ('MESH:D002439', 'Chemical') :: ['cefotaxime']

entities_list: @entity800 :: ('MESH:D015242', 'Chemical') :: ['levofloxacin']

entities_list: @entity497 :: ('MESH:D003147', 'Disease') :: ['community']

entities_list: @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae strain']

answer: @entity55 :: (MESH:D011014,Disease) :: ['pneumonia']


abstract: OBJECTIVE: To investigate the impact of aquatic exercise on pressure @entity158 threshold in @entity0 survivors with hormone therapy-associated @entity4841 . DESIGN: Single-blind, controlled trial. SETTING: Two major metropolitan hospitals and a Sport and @entity11028 Club in Granada, Spain. SUBJECTS: Forty @entity1 aged 29-71 years with @entity0 who reported @entity4841 . INTERVENTION: @entity1 were allocated alternately to either aquatic exercise in a chest-high pool or usual care while on the waiting list; control @entity1 received treatment later. The two-month hydrotherapy intervention consisted of 24 sessions 3 days per week. Each session included 5 minutes of warm-up, 15-20 minutes of aerobic exercise, 15 minutes of mobility exercise and 20 minutes of recovery techniques. MAIN MEASURES: Pressure @entity158 threshold at neck, shoulder, hand and leg were evaluated as primary outcomes. @entity5 , as measured by the Piper Fatigue Scale, body mass index and waist circumference were secondary outcomes. A 2   2 repeated-measure ANCOVA was used in this study. RESULTS: No adverse events or development of worsening of @entity158 was observed. Almost all the @entity1 in the intervention group (89%) adhered to the hydrotherapy programme. @entity1 experienced a decrease in pressure @entity158 threshold measured in neck, hand, shoulder and leg, as measured by algometry pressure, and waist circumference; all P < 0.05. @entity5 (P = 0.06) and body mass index (P = 0.42) did not show significant improvement. CONCLUSIONS: These data suggest that hydrotherapy in a chest-high pool may reduce the @entity158 threshold and waist circumference in @entity0 survivors with hormone therapy-associated @entity4841 .

title: Aquatic exercise in a chest-high pool for hormone therapy-induced XXXX in @entity0 survivors: a pragmatic controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Patients', 'patients', 'Participants']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['stage I-III breast cancer', 'breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer-related fatigue']

entities_list: @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgia']

answer: @entity4841 :: (MESH:D018771,Disease) :: ['arthralgia']


abstract: OBJECTIVE: To examine the effect of @entity2399 ( @entity2400 ) on sFlt (soluble fms-like @entity669 kinase)-1 in the fetal and maternal compartments of normotensive and preeclamptic placentas. METHODS: Cotyledons of term normotensive and preeclamptic placentas were dually perfused for six hours, with control medium and @entity2400 (6-7 mg %) in the maternal reservoir. Perfusate sFlt-1 concentrations were measured. RESULTS: Median sFlt-1 concentration was higher in the maternal than in the fetal side in both groups and perfusion media (p < 0.0001). When perfused with control medium, the maternal side median sFlt-1 concentration was higher in the @entity1468 than in the control group (p < 0.0001). After perfusion with @entity2400 , the median maternal and fetal sides perfusate sFlt-1 concentration were higher in the @entity1468 than in the control group (p < 0.0001). In comparison to perfusion with control medium, the median sFlt-1 concentration of normal pregnant @entity1 decreased in the fetal and increased in the maternal side. In the @entity1468 group, only median fetal side sFlt-1 concentration increased. CONCLUSION: In contrast to normal pregnant @entity1 , perfusion with @entity2400 of preeclamptic placentas did not increase their sFlt-1 concentration. This may indicate that @entity2400 role may be limited to its anti-eclamptic and does not affect the anti-angiogenic state associated with @entity1468 .

title: Perfusion with @entity2399 increases sFlt-1 secretion only in the fetal side of placenta of XXXX with @entity1468 .

entities_list: @entity2399 :: ('MESH:D008278', 'Chemical') :: ['magnesium sulfate']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: The anti-arrhythmic agent @entity2643 (AD) is associated with numerous adverse effects, but serious @entity409 is rare. The improved safety of administration of daily low doses of AD has already been established and this regimen is used for long-term medication. Nevertheless, asymptomatic continuous @entity99 by AD may increase the risk of step-wise progression of @entity1561 . We present an autopsy case of AD-induced @entity1575 in a @entity1 who had been treated with a low dose of AD (200 mg/d) daily for 84 mo. The @entity1 was a 85-year-old male with a history of @entity741 . Seven years after initiation of treatment with AD, he was admitted with cardiac congestion. The total dose of AD was 528 g. Mild elevation of serum aminotransferase and @entity382 were present. Liver biopsy specimens revealed @entity82 , and under electron microscopy numerous lysosomes with electron-dense, whorled, lamellar inclusions characteristic of a secondary phospholipidosis were observed. Initially, withdrawal of AD led to a slight improvement of serum aminotransferase levels, but unfortunately his general condition deteriorated and he died from complications of @entity55 and @entity177 . Long-term administration of daily low doses of AD carries the risk of progression to irreversible @entity99 . Therefore, periodic examination of liver function and/or liver biopsy is required for the management of @entity1 receiving long-term treatment with AD.

title: @entity1575 induced by long-term administration of a daily low dose of XXXX : a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity1561 :: ('MESH:D065626', 'Disease') :: ['non-alcoholic fatty liver disease']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['ischemic heart disease']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['liver injury']

answer: @entity2643 :: (MESH:D000638,Chemical) :: ['amiodarone']


abstract: Blockade of kappa-opioid receptors in the @entity5702 ( @entity5702 ) with @entity14719 ( @entity14719 ) stimulates luteinizing hormone (LH) release during midpregnancy in the @entity35 [48]. The objective of this study was to determine whether @entity1063 (NE) or @entity935 (DA) mediates the LH response to blockade of @entity5702 kappa-opioid receptors on days 13-17 of pregnancy in the @entity35 . Two experiments were conducted. In the first, push-pull perfusion in conjunction with HPLC was used to monitor in vivo NE release in the @entity5702 occurring in response to (a) artificial @entity7421 followed by @entity7421 containing nor-BNI (40 micrograms/h), (b) @entity5829 ( @entity9956 , a NE reuptake blocker, 10 microM) in @entity7421 followed by @entity9956 , and (c) @entity9956 followed by @entity9956 +nor-BNI. Blood samples were taken at 12 min intervals concurrent with push-pull perfusate samples. Plasma LH levels were determined by RIA. Nor-BNI significantly increased LH release compared to @entity7421 alone, but perfusate NE was undetectable in either perfusion period. However, perfusion with @entity7421 containing 100 mM K+ in these @entity35 markedly increased perfusate NE levels, indicating noradrenergic nerve terminals were present at the perfusion sites in the @entity5702 . Addition of @entity9956 to the @entity7421 significantly increased perfusate NE levels, but produced no change in LH release. Nor-BNI+ @entity9956 perfusion increased LH secretion similar to nor-BNI alone, but produced no additional increase in @entity5702 perfusate NE levels compared to perfusion with @entity9956 alone.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Lack of catecholamine involvement in the increased luteinizing hormone release due to blockade of kappa-opioid receptors in the XXXX during midpregnancy in the @entity35 .

entities_list: @entity5829 :: ('MESH:D003891', 'Chemical') :: ['desipramine']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity14719 :: ('MESH:C051844', 'Chemical') :: ['nor-BNI', 'nor-binaltorphimine']

entities_list: @entity5702 :: ('MESH:D018295', 'Disease') :: ['MBH', 'medial basal hypothalamus']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity5702 :: (MESH:D018295,Disease) :: ['medial basal hypothalamus']


abstract: OBJECTIVE: The purpose of this study was to determine the risks for fetal exposure to oral pathogens and the relationship between @entity3556 and fetal exposure in @entity600 risk. STUDY DESIGN: An analysis of prospectively collected data for the longitudinal Oral Conditions and Pregnancy Study was conducted. Maternal factors that potentially were associated with fetal exposure to oral pathogens (defined as detection of umbilical cord serum Immunoglobulin M to 1 of 5 oral pathogens) were examined, and the role of @entity3556 and fetal exposure to oral pathogens in @entity600 risk was explored. Preterm birth was defined as delivery at <35 weeks of gestation. An adjusted relative risk (95% CI) for fetal exposure was calculated. Adjusted hazard ratios (95% CI) were calculated for @entity600 among @entity1 whose data were stratified by the presence/absence of @entity548 and/or fetal exposure to oral pathogens. RESULTS: There were complete data for 661 @entity1 ; 230 @entity1 (34.8%) with and 431 @entity1 (65.2%) without fetal exposure to oral pathogens. In multivariable analysis, first- or second-trimester @entity548 and white race were associated significantly with fetal exposure to oral pathogens (adjusted relative risk, 1.8 [95% CI, 1.3-2.5] and 1.3 [95% CI, 1.1-1.7], respectively). The adjusted hazard ratio for @entity600 among @entity1 with first- or second-trimester @entity548 and fetal exposure to oral pathogens was 6.4 (95% CI: 2.6-16.0). CONCLUSION: @entity3556 is associated with fetal exposure to oral pathogens, which increases @entity600 risk. Whether @entity548 is the cause of or result of fetal exposure to oral pathogens remains to be determined.

title: Antepartum @entity3556 , fetal exposure to oral pathogens, and risk for XXXX at <35 weeks of gestation.

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal bleeding', 'Vaginal bleeding']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['preterm birth']

answer: @entity600 :: (MESH:D000014,Disease) :: ['preterm birth']


abstract: CONTEXT: @entity263 is a public health problem in Spain and in the Western world. Bone involvement, associated to significant morbidity, is practically constant in the advanced stages of the disease. This work aims to review the prognostic factors used in the usual clinical practice that predict the development of bone @entity3 and to analyze the follow-up and treatment option in these @entity1 profiles. ACQUIRING OF EVIDENCE: We performed a review of the literature on the useful factors in the context of therapy with intention to cure. We included the classical clinical values in the diagnosis (PSA, clinical stage, Gleason score on the biopsy) pathological factors (pT stage, margins, @entity150 , @entity5 volume, lymph node involvement) and PSA kinetics in their different contexts and the histological and molecular parameters. SYNTHESIS OF EVIDENCE: The @entity5 differentiation "Gleason" score and PSA are the most important predictive factors in the prediction of bone @entity3 in @entity1 with intention to cure. Kinetic factors such as PSA doubling time (TDPSA) < 8 months or PSA > 10 ng/ml in the case of @entity263 ( @entity263 ), are predictive factors for the development of @entity3 . @entity4381 and denosumab have demonstrated their effectiveness for the treatment of @entity79 in randomized studies. CONCLUSIONS: There are predictive factors within the usual clinical practice that make it possible to recognize the " @entity1 at risk" to develop bone @entity3 . The currently available treatments, @entity4381 or denosumab, can help us in the management of the @entity1 at risk of developing @entity3 or metastatic @entity1 , increasing the quality of life and decreasing skeletal events.

title: Factors that predict the development of bone @entity3 due to XXXX : Recommendations for follow-up and therapeutic options.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['castration-resistant prostate cancer', 'CPRC', 'Prostate cancer']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder invasion']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases', 'metastatic disease']

entities_list: @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronic acid', 'Zoledronic acid']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: A total of 29 @entity21650 @entity1 were treated by endoscopic sinus surgery between 1990 and 1995. After the surgery, a 7 to 10-day course of systematic @entity4028 was administered. Two cases were excluded, due to later occurrence of @entity706 in one @entity1 and incompleteness of postoperative antibiotic therapy in the other. Among those included, @entity21650 occurred in the absence of prior surgery in 24 @entity1 , and the condition was secondary to a previous intranasal surgery in the other three @entity1 . After a 1 to 6-year follow-up (mean: 63.4 months), seven @entity1 were successfully managed without any characteristic symptom or sign of @entity21650 . Another 18 @entity1 felt improved. Only two @entity1 did not have any improvement. The rate of improvement was 92.6%. Overall, one @entity1 suffered from a @entity1410 after operation. Exposed orbital fat was observed in the other @entity1 . The orbital complication rate was therefore 7.4%. No other major complication occurred in this series. The bacteriologic, radiological, antroscopic, and pathologic findings are also included here. It is concluded that endoscopic sinus surgery in combination with adequate postoperative antibiotic therapy can significantly treat @entity21650 .

title: Endoscopic sinus surgery and postoperative intravenous aminoglycosides in the treatment of XXXX .

entities_list: @entity21650 :: ('MESH:D012222', 'Disease') :: ['atrophic rhinitis']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['nasal lymphoma']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['left retrobulbar hematoma']

entities_list: @entity4028 :: ('CHEBI:47779', 'Chemical') :: ['aminoglycoside']

answer: @entity21650 :: (MESH:D012222,Disease) :: ['atrophic rhinitis']


abstract: Pathogenesis of @entity16 was studied from the standpoint of @entity1333 . In @entity751 , @entity4216 multiplex is the most specific @entity1897 . It occurs most frequently in @entity10763 . Among them, the incidence is highest in microscopic polyangitis (MPO), @entity12534 ( @entity12534 ), and @entity2883 ( @entity2883 ). All of them are categorized as ANCA associated disease. Because the disease activity is parallel with ANCA titer and ANCA is related directory to the pathogenesis of @entity1333 as well as the occurrence of @entity1897 . Other @entity10763 , such as lupus or @entity12299 which are believed to occur by immune complex mechanism, are accompanied seldom by @entity1897 . In @entity2883 , there are @entity75 in upper and lower respiratory tracts which are supposed to be induced by @entity1198 dominant @entity404 T cell infiltration. In cases of @entity1201 , if @entity1897 were related to @entity10763 , there might be two different pathogenesis. One is @entity1333 like @entity2883 in tuberculoid type. The other is immune @entity1333 like @entity1252 in @entity1203 , especially ENL. The site of these events may be small vessel in epineurium. Further immunologic studies are needed to clarify detailed mechanisms of @entity16 .

title: [ XXXX --observation from the standpoint @entity1333 ].

entities_list: @entity1203 :: ('MESH:D015440', 'Disease') :: ['lepromatous type']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['necrotizing vasculitis', 'vasculitis', 'granulomatous vasculitis', 'complex type necrotizing vasculitis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['granulomatous lesions']

entities_list: @entity12534 :: ('MESH:D015267', 'Disease') :: ['CSS', 'Churg-Strauss Syndrome']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['leprous neuropathy']

entities_list: @entity10763 :: ('MESH:C565222', 'Disease') :: ['small vessel vasculitis']

entities_list: @entity12299 :: ('MESH:D056653', 'Disease') :: ['rheumatoid vasculitis']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral nerve injury', 'peripheral neuropathy']

entities_list: @entity751 :: ('MESH:D013577', 'Disease') :: ['vasculitic syndrome']

entities_list: @entity4216 :: ('MESH:D020422', 'Disease') :: ['mononeuritis']

entities_list: @entity2883 :: ('MESH:D014890', 'Disease') :: ['WG', "Wegener's granulomatosis"]

answer: @entity16 :: (MESH:D009422,Disease) :: ['Leprous neuropathy']


abstract: In @entity1 with @entity548 @entity2312 from causes other than @entity715 , endoscopic sclerotherapy and ablative surgery have yielded poor results. Over a 3-year period starting in June 1989, a total of 30 distal splenorenal shunts were performed prospectively on 19 paediatric and 11 adult @entity1 with @entity1578 . The mean (s.d.) age was 17(12) (range 6-50) years; there were 20 male and ten female @entity1 of whom six had @entity82 , four non-cirrhotic portal @entity82 and 20 portal vein @entity715 . Two @entity1 died and two more had shunt @entity715 ; all four were considered failures of treatment. @entity6118 was present in 15 @entity1 but reverted to normal in 13. In 26 @entity1 the @entity2312 disappeared. Concomitant oesophageal varices were present in 22 @entity1 and showed marked regression, with no rebleeding over a mean (s.d.) follow-up of 21(10) (range 7-39) months. A distal splenorenal shunt was effective in controlling gastric variceal @entity548 in 26 of 30 @entity1 in whom liver function was well preserved.

title: Distal splenorenal shunting for @entity548 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis', 'cirrhosis']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding', 'haemorrhage']

entities_list: @entity1578 :: ('MESH:D017093', 'Disease') :: ['bleeding gastric varices and good liver function']

entities_list: @entity6118 :: ('MESH:D006971', 'Disease') :: ['Hypersplenism']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['splenic vein thrombosis', 'thrombosis']

entities_list: @entity2312 :: ('MESH:D004932', 'Disease') :: ['gastric varices']

answer: @entity2312 :: (MESH:D004932,Disease) :: ['gastric varices']


abstract: OBJECTIVE: To investigate the relationship between serum @entity7 ( @entity7 ) and clinicopathological factors and to determine whether @entity7 is an independent prognostic factor of @entity43 @entity1 . METHODS: Fifty-six @entity1 with International Federation of Gynecology and Obstetrics stages I to @entity43 undergoing surgery were enrolled. Clinical and pathologic items were recorded. Pretreatment @entity7 serum samples of the 56 @entity1 were measured by an enzyme-linked immunosorbent assay. The results were correlated to clinical data. The histopathologic items and serum @entity7 influencing clinical outcome were evaluated comparatively. RESULTS: The median @entity7 serum level in @entity43 @entity1 was 458.7 pg/mL. The 75% quatile was defined as the cutoff level. Elevated @entity7 serum levels before therapy correlated significantly with poorer @entity66 ( @entity66 ) (log rank test, P = 0.001) and @entity1349 ( @entity1349 ) (log rank test, P < 0.001) on all of the 56 @entity1 . Besides, significantly reduced @entity66 (log rank test, P = 0.001) and OR (log rank test, P = 0.006) were also observed on 40 @entity1 with @entity66 less than 2 cm. High histologic grade (RR = 2.24 for @entity66 ; RR = 2.38 for @entity1349 ) and elevated serum @entity7 levels (RR = 3.34 for @entity66 ; RR = 4.47 for @entity1349 ) are the prognostic factors on the 56 @entity43 @entity1 by multivariate analyses. The advanced surgical staging (RR = 3.28 for @entity66 ; RR = 3.84 for @entity1349 ), high histologic grade (RR = 2.55 for @entity66 ; RR = 2.44 for @entity1349 ), and elevated serum @entity7 levels (RR = 5.62 for @entity66 ; RR = 5.37 for @entity1349 ) are the prognostic factors for 40 @entity43 @entity1 with @entity66 less than 2 cm by multivariate analyses. CONCLUSIONS: Pretreatment @entity7 serum levels might be regarded as an additional factor in predicting the outcome of @entity43 @entity1 . It also could provide prognostic information in clinically relevant subsets, such as those of @entity66 less than 2 cm. Anti-angiogenic therapy, if is available, might be a new treatment modality for @entity43 @entity1 with poor prognosis predicted by @entity7 and other clinical parameters.

title: Serum @entity7 in epithelial XXXX : correlation with @entity1 survival.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian cancer', 'IV epithelial ovarian cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease', 'DFS', 'disease-free survival']

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian neoplasms']


abstract: @entity75 ( @entity12523 or IME) is a rare clinical syndrome associated with occult @entity521 in 20%-50% of all cases. IME is the initial presentation of @entity521 in 1%-3% of @entity1 . Imaging approaches including chest radiography and abdominal computed tomography (CT) have been proposed to detect @entity521 in IME. @entity7990 ( @entity7990 ) is highly effective in the detection of @entity521 . These scans can identify both soft-tissue and skeletal lesions anywhere in the body. Our purpose was to attempt to determine the best screening method for detection of occult @entity521 in @entity1 with IME. Records of all @entity521 @entity1 from 1983 to May 1991 were reviewed. Four cases of IME with @entity521 were identified in which imaging studies included an MIBG scan. All four @entity1 had positive MIBG scans (100%) while only two had masses on initial CT (50%). In the three @entity1 initially evaluated by traditional methods, the mean time to diagnosis and the mean number of advanced radiologic studies were 7.5 mo and 7.3 studies respectively. The @entity1 screened with MIBG had only cranial and abdominal CT prior to surgery. Although based on a limited number of @entity1 , results suggest that MIBG may prove to be a useful screening procedure in @entity1 with IME. Traditional imaging modalities can then be directed to evaluate sites of disease identified by MIBG scans.

title: Optimized diagnostic strategy for XXXX in @entity12523 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Infantile myoclonic encephalopathy']

entities_list: @entity7990 :: ('MESH:D019797', 'Chemical') :: ['Metaiodobenzylguanidine', 'MIBG']

entities_list: @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma']

entities_list: @entity12523 :: ('MESH:D053578', 'Disease') :: ['opsoclonus-myoclonus']

answer: @entity521 :: (MESH:D009447,Disease) :: ['neuroblastoma']


abstract: OBJECTIVE: To compare and contrast the efficacy and tolerability of a proton pump inhibitor, @entity10112 , to that of an H2 antagonist, @entity5616 , in the treatment of @entity1 with mild to severe @entity354 . BACKGROUND: @entity354 is a common illness affecting 5-10% of the world's population. Acid reflux plays a major role in the disease's genesis, as do esophageal and gastric motility disturbances. METHODS: 315 @entity1 (intent to treat) with endoscopically confirmed @entity354 ( @entity40435 ( @entity40435 ) stages II and III) were recruited to the study by 46 mexican investigators in nine centers. @entity1 received either @entity10112 40 mg once daily or @entity5616 150 mg twice daily in this double blind, randomized, parallel group study. @entity1 not achieving complete endoscopic healing after four weeks of therapy received an additional four weeks of treatment. Drug tolerability was assessed by adverse event reporting during the study. RESULTS: After four weeks @entity10112 therapy, 81% of @entity1 with @entity40435 II and 67% of the @entity1 with @entity40435 III were healed; in contrast @entity5616 healed only 67 and 30% of the @entity1 respectively, all results expressed on an per-protocol basis. After eight weeks therapy the healing rates for @entity10112 group increased to 94% and the @entity5616 group to 74% (p = 0.001). The incidence of adverse events was less than 2% in both treatment groups, thus both therapies were found to be well tolerated. CONCLUSIONS: @entity10112 is superior to @entity5616 in the treatment of mild to severe @entity354 and is equally well tolerated.

title: [Clinical superiority of @entity10112 over XXXX in the treatment of @entity354 grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican @entity10112 Study Group].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity40435 :: ('MESH:C537680', 'Disease') :: ['SM', 'Savary-Miller']

entities_list: @entity10112 :: ('MESH:C064276', 'Chemical') :: ['Pantoprazole', 'pantoprazole']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['reflux esophagitis', 'Reflux esophagitis']

entities_list: @entity5616 :: ('MESH:D011899', 'Chemical') :: ['ranitidine']

answer: @entity5616 :: (MESH:D011899,Chemical) :: ['ranitidine']


abstract: Since extremely low frequency (i.e., 50- or 60-Hz) magnetic fields (MFs) from overhead power lines and other electromagnetic sources are ubiquitous in modern societies, the possible carcinogenic effect of such fields recently suggested by epidemiological studies has engendered much concern. However, in view of various unknown and uncontrolled variables which may bias epidemiological studies on MF interactions, a causal relationship between MFs and tumorigenesis can only be determined precisely in animal experiments. The goal of the study reported here was to determine if low frequency MFs at the low flux densities which are relevant for @entity1 populations induce @entity5 -promoting or copromoting effects in a model of @entity0 . Furthermore, since reduction in pineal production of @entity2493 has been implicated as a cause of @entity5 promotion by electromagnetic fields, determinations of nocturnal @entity2493 peak levels in serum were performed during MF exposure. @entity5 were induced by intragastric administration of 20 mg (5 mg/week) @entity3653 ( @entity106 ) in female @entity35 . Groups of 36 @entity35 were either sham-exposed or exposed for 91 days at a 50-Hz gradient MF of 0.3-1 microT, which is a relevant range for elevated domestic MF exposure as arising from neighboring power lines. Nocturnal @entity2493 levels were significantly reduced by exposure to this weak alternating MF. However, histopathological evaluation of mammary lesions did not disclose any significant difference between MF- and sham-exposed animals. Incidence of @entity5 was 61% in controls versus 67% in MF-exposed @entity35 . The predominant @entity5 type was the invasive @entity420 , which was found in 21 @entity35 of both groups. Examination of @entity5 size did not indicate significant differences in @entity5 burden between both groups. Furthermore, the incidence of @entity1613 was not altered by MF exposure. Thus, the data of this study indicate that alternating MF do not exert significant @entity5 promoting or copromoting effects at environmentally relevant flux densities in the @entity35 mammary @entity5 system.

title: Effects of weak alternating magnetic fields on nocturnal @entity2493 production and mammary carcinogenesis in XXXX .

entities_list: @entity3653 :: ('CHEBI:254496', 'Chemical') :: ['7,12-dimethylbenz(a)anthracene']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'mammary tumors', 'Mammary tumors', 'cancer']

entities_list: @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin']

entities_list: @entity1613 :: ('MESH:D011230', 'Disease') :: ['preneoplastic lesions']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: BACKGROUND: @entity1697 ( @entity1697 ) therapy is increasingly prescribed as a non-continuous positive airway pressure treatment modality for @entity387 ( @entity387 ). Although @entity1697 therapy is reported to be efficacious for the treatment of @entity387 , data on compliance remain limited to self-report. METHODS: In this 3-month prospective clinical trial, the main outcome was to assess the safety and feasibility of an objective measurement of compliance during @entity1697 therapy using an embedded microsensor thermometer with on-chip integrated readout electronics in 51 consecutive @entity1 with an established diagnosis of @entity387 (AHI 18.0    11.9/h; age 47    10 y; BMI 26.6    4.0 kg/m(2); @entity1 / @entity1 : 31/20). @entity1 were unaware of the purpose of the study. RESULTS: No microsensor-related adverse events were recorded. In addition, no problems were encountered during the readout of the compliance data. Out of 51 microsensors, one had a technical defect and was lost to follow-up. In this study, the overall objective mean rate of @entity1697 use was 6.6    1.3 h per day with a regular @entity1697 users' rate of 82% at the 3-month follow-up. Statistical analysis revealed no significant differences between objective and self-reported @entity1697 compliance data in this study. Measurement of the objective @entity1697 compliance allowed us to calculate the mean disease alleviation ( @entity1865 ) as the product of objective compliance and therapeutic efficacy. @entity1865 serves as a measure of the overall therapeutic effectiveness, and turned out to be 51.1%. CONCLUSIONS: The results illustrate the safety and feasibility of objective measurement of @entity1697 compliance. The objective measurement of @entity1697 compliance allows for calculation of the @entity1865 .

title: Objective measurement of compliance during oral appliance therapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity1697 :: ('MESH:D009062', 'Disease') :: ['Oral appliance', 'OA']

entities_list: @entity387 :: ('MESH:D012891', 'Disease') :: ['sleep-disordered breathing', 'SDB']

answer: @entity387 :: (MESH:D012891,Disease) :: ['sleep-disordered breathing']


abstract: OBJECTIVE: To investigate functions of flgDxoc and flgExoc genes regulated by diffusible signal factor (DSF) in @entity16990 . oryzicola(Xoc)Rs105. METHODS: TheflgDxoc and flgExoc genes were amplified by PCR. We constructed deltaflgDxoc and deltaflgExoc, the deletion mutants from Rs105 by using double crossover method, and determined cell morphology, motility, pathogenicity in host @entity579 and hypersensitive response (HR) in nonhost @entity286 . We tested the differential expression of flgDxoc and flgExoc gene by reverse transcriptional polymerase chain reaction (RT-PCR) between the wide type and deltarpfFxoc (the deletion mutant of rpfFxoc gene, which could not produce DSF). RESULTS: We cloned flgDxoc and flgExoc from genomic DNA of Rs105. PCR and Southern blot analysis demonstrated that the flgDxoc and flgExoc genes were knocked out successfully. Both mutants were non-flagellated and significantly attenuated motility on the 0.3% semi-solid medium. The pathogenicity on @entity579 were obviously attenuated in deltaflgDxoc and deltaflgExoc compared to the wild type. All the changes in mutant could be restored through the complementation. However, there was no significant difference in bacterial growth in MMX medium and induction of HR between mutant (deltaflgDxoc or deltaflgExoc) and the wild type. In addition, the results of RT-PCR demonstrated that the transcription level of flgDxoc and flgExoc were downregulated in deltarpfFxoc. CONCLUSION: This study showed that expressions of flgDxoc and flgExoc were positively regulated by DSF, and necessary for flagellar hook assembly and flagellar structure in Xoc. Meanwhile, FlgD and FlgE contributed to pathogen's virulence, motility and @entity6722 , but no differences at growth rate in MMX medium and HR in nonhost. In addition, our results provided molecular evidences that the contribution of DSF-type quorum sensing to pathogen's virulence might be, at least partially, dependent on bacterial flagellar in Xoc.

title: [Analysis of the flgD and figE genes regulated by diffusible signal factor in XXXX pv. oryzicola].

entities_list: @entity6722 :: ('MESH:C565534', 'Disease') :: ['chemotaxis']

entities_list: @entity16990 :: ('347', 'Species') :: ['Xanthomonas oryzae pv']

answer: @entity16990 :: (347,Species) :: ['Xanthomonas oryzae']


abstract: BACKGROUND: With improved cure rates of @entity5 in @entity1 and adolescents, the long-term effects of oncological treatment, including impaired fertility, have become an important clinical issue. METHODS: In 2008, we conducted a nationwide survey in Germany in which we asked 4689 female and male @entity1 who had been treated for @entity5 in childhood or adolescence for information on menstruation, previous fertility testing (if any), attempts to conceive, and pregnancies. In a complementary study carried out in 2009, 748 former @entity5 @entity1 in Berlin were offered hormone testing and sperm analysis. The defined criteria for suspected @entity249 were, in women, anti-muellerian hormone levels below 0.1 ng/mL; in @entity1 , FSH levels above 10 IU/L and inhibin B levels below 80 pg/mL, or @entity3893 . RESULTS: The respondents to the nationwide survey included 1476 @entity1778 survivors and 1278 @entity1 who had had a solid @entity5 . 104 former @entity1778 @entity1 and 96 former solid @entity5 @entity1 had already undergone fertility testing, leading to the suspicion of @entity249 in 26% and 34% of the @entity1 in these respective groups (95% confidence intervals [CI], 18%-34% and 25%-43%). The @entity1 who were tested in the Berlin study included 59 @entity1778 survivors and 104 @entity1 who had had a solid @entity5 . The frequency of suspected @entity249 in these two groups was 25% and 27%, respectively (95% CI, 14%-36% and 18%-36%). CONCLUSION: Up to one-third of adults who undergo fertility testing after having been treated for @entity5 in childhood or adolescence have suspected @entity249 . @entity1 and their parents should be counseled about the possibility of @entity249 and about fertility-preserving measures.

title: @entity249 after treatment for @entity1778 and XXXX in childhood and adolescence.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients', 'persons', 'men']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity3893 :: ('MESH:D053713', 'Disease') :: ['azoospermia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['solid tumors']


abstract: Bacterial strains of @entity6464 included in the recognized subsp. acromogenes, subsp. masoucida, and subsp. smithia in addition to the large number of strains not included in any of the described subspecies are referred to as atypical A. salmonicida. The atypical strains form a very heterogeneous group with respect to biochemical characteristics, growth conditions, and production of extracellular proteasess. Consequently, the present taxonomy of the species A. salmonicida is rather ambiguous. Atypical A. salmonicida has been isolated from a wide range of cultivated and wild fish species, non-salmonids as well as salmonids, inhabiting fresh water, brackish water and marine environments in northern and central Europe, South Africa, North America, Japan and Australia. In non-salmonid fish species, infections with atypical strains often manifest themselves as superficial skin ulcerations. The best known diseases associated with atypical A. salmonicida are @entity7136 @entity7136 erythrodermatitis, @entity2083 @entity2083 @entity1066 , and @entity1066 of flounder Platichthys flesus, but atypical strains are apparently involved in more disease outbreaks than previously suspected. Macroscopical and microscopical studies of ulcerated fish indicate internal organs are infrequently invaded by atypical A. salmonicida. This view is supported by the fact that atypical strains are irregularly isolated from visceral organs of ulcerated fish. High mortality caused by atypical A. salmonicida has been observed in populations of wild non-salmonids and farmed salmonids, although the association between the mortality in the wild fish stocks and atypical A. salmonicida has not always been properly assessed. In injection experiments the pathogenicity of the atypical strains examined showed large variation. An extacellular A-layer has been detected in different atypical strains, but virulence mechanisms different from those described for (typical) A. salmonicida subsp. salmonicida, for example an extracellular metallo-protease and a different @entity68 utilization mechanism, have been described. Limited information is available about the ecology, spread and survival of atypical strains in water. The commonly used therapeutic methods for the control of diseases in farmed fish caused by atypical A. salmonicida are generally effective against the atypical strains. Resistance to different antibiotics and transferable plasmid encoding multiple drug resistance have been observed in atpical A. salmonicida. Studies aimed at producing a vaccine against atypical strains are in progress.

title: Occurrence and significance of atypical XXXX in non-salmonid and salmonid fish species: a review.

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer disease']

entities_list: @entity6464 :: ('645', 'Species') :: ['Aeromonas salmonicida']

entities_list: @entity7136 :: ('7962', 'Species') :: ['carp', 'Cyprinus carpio']

entities_list: @entity2083 :: ('7957', 'Species') :: ['goldfish', 'Carassius auratus']

answer: @entity6464 :: (645,Species) :: ['Aeromonas salmonicida']


abstract: OBJECTIVE: To investigate the the expression and @entity519 regulation of vascular endothelial growth factor( @entity7 ) and matrix metalloproteinase-9. METHODS: @entity7 mRNA and @entity1495 mRNA were examined by reverse transcription-polymerase chain reaction (RT-PCR) in 43 @entity418 specimens including 18 para-tumorous esophageal tissues. The expression of @entity7 protein and mean @entity2101 ( @entity2101 ) in 56 specimens were examined by immunohistochemical stain. The effect of @entity519 on @entity7 and @entity1495 expression in @entity418 cell lines was quantitatively determined by enzyme linked immunosorbent assay (ELISA). RESULTS: The @entity7 expression in the tumorous tissue, being significantly correlated with @entity2101 in the @entity5 , was remarkably higher than that in the para-tumorous tissue. @entity7 and @entity2101 expression in the @entity5 was significantly associated with stage and @entity3 of @entity418 . The @entity1495 expression in the tumorous tissue, being uncorrelated with vessel count and clinicopathologic features in @entity418 , was significantly higher than that in the para-tumorous tissue. @entity519 significantly increased the @entity7 expression in @entity418 cell lines but did not affect the @entity1495 expression. CONCLUSIONS: The expression of @entity7 plays an important role in the angiogenesis and @entity3 of @entity418 , which is regulated by @entity519 . @entity7 may serve as a predictor of progression in @entity418 and a potential target for antiangiogenic therapy of @entity418 .

title: [Expression and XXXX regulation of vascular endothelial growth factor and matrix metalloproteinase-9 in @entity418 ].

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['Hypoxia', 'hypoxic', 'hypoxia']

entities_list: @entity2101 :: ('MESH:C538394', 'Disease') :: ['microvessel density', 'MVD']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer', 'esophageal carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity519 :: (MESH:D000860,Disease) :: ['hypoxic']


abstract: Our primary objective was to assess the feasibility of geriatric @entity1 (>65 yr) bypassing the postanesthesia care unit (PACU) after ambulatory surgery. A secondary objective was to compare recovery profiles when using three different maintenance anesthetics. Ninety ASA physical status I--III consenting outpatients (>65 yr) undergoing short urologic procedures were randomly assigned to one of three anesthetic treatment groups. After a standardized induction with @entity3575 and @entity1875 , anesthesia was maintained with @entity1875 (75-150 microg center dot kg(-1) center dot min(-1) IV), @entity5161 (0.7%-1.2% end tidal), or @entity10233 (3%-6% end tidal), in combination with @entity3810 70% in @entity26 . In all three groups, the primary anesthetic was titrated to maintain an electroencephalographic-bispectral index value of 60-65. Recovery times, postanesthesia recovery scores, and therapeutic interventions in the PACU were recorded. Although emergence times were similar in the three groups, the time to achieve a fast-track discharge score of 14 was significantly shorter in @entity1 receiving @entity10233 compared with @entity1875 and @entity5161 (22 +/- 23 vs 33 +/- 25 and 44 +/- 36 min, respectively). On arrival in the PACU, a significantly larger percentage of @entity1 receiving @entity10233 were judged to be fast-track eligible compared with those receiving either @entity5161 and @entity1875 (73% vs 43% and 44%, respectively). The number of therapeutic interventions in the PACU was also significantly larger in the @entity5161 group when compared with the @entity1875 and @entity10233 groups (21 vs 11 and 7, respectively). In conclusion, use of @entity10233 for maintenance of anesthesia should facilitate PACU bypass ("fast-tracking") of geriatric @entity1 undergoing short urologic procedures. IMPLICATIONS: Geriatric outpatients undergoing brief urologic procedures more rapidly achieve fast-tracking discharge criteria after @entity10233 (versus @entity5161 and @entity1875 ) anesthesia. Use of @entity5161 was also associated with an increased need for nursing interventions in the early recovery period compared with @entity10233 and @entity1875 .

title: Fast-track eligibility of geriatric XXXX undergoing short urologic surgery procedures.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity10233 :: ('MESH:C053562', 'Chemical') :: ['desflurane', 'Desflurane']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'Propofol']

entities_list: @entity3810 :: ('MESH:D009609', 'Chemical') :: ['nitrous oxide']

entities_list: @entity5161 :: ('MESH:D007530', 'Chemical') :: ['Isoflurane', 'isoflurane']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Radiation therapy for @entity5 of the head and neck is associated with significant side effects involving the oral cavity. For example, radiation therapy leads to reduced vascularity and @entity26 tension of the oral hard and soft tissues and also to salivary gland dysfunction. These changes increase the risk of @entity1547 and lead to reduced healing capacity following oral surgery procedures. A severe complication of radiation therapy is @entity7190 of the jaw bone. The purpose of this paper is to review preradiation oral examination and treatment. @entity1 management regarding @entity66 prior to radiation therapy has to accomplish a number of goals: (1) to identify existing @entity66 and potential risk of @entity66 , (2) to remove @entity166 before the start of radiation therapy, (3) to prepare the @entity1 for the expected side effects with information about them, (4) to establish an adequate standard of oral hygiene to meet the increased challenge, (5) to provide a plan for maintaining oral hygiene and @entity1388 treatment, for oral rehabilitation, and for follow-up and (6) to inform the @entity1 about the availability of any financial support for dental treatment, and finally (7) to establish the necessary multidiciplinary collaboration within the health care system so that oral symptoms and sequelae before, during and after the radiation therapy can be reduced or alleviated. The methods used to accomplish these goals may vary between @entity5 centers. Each center should have a multidisciplinary team to handle such problems. After the end of radiation therapy most of the dental treatments in our @entity1 are done by private dentists, except for some oral surgery procedures, which are performed in hospital. In our experience, the major challenge in this process is related to (1) informing of the @entity1 , (2) timing the coordination between all the health care workers involved, (3) establishing an adequate schedule for dental treatment and follow-up, and (4) securing @entity1 compliance to prevent or reduce the oral side effects.

title: Management of XXXX prior to radiation therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['oral disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumors', 'cancer']

entities_list: @entity7190 :: ('MESH:D010025', 'Disease') :: ['osteoradionecrosis']

entities_list: @entity1547 :: ('MESH:D003731', 'Disease') :: ['dental decay and oral infections']

entities_list: @entity1388 :: ('MESH:D005459', 'Chemical') :: ['fluoride']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious dental/oral foci']

answer: @entity66 :: (MESH:D004194,Disease) :: ['oral disease']